| June 1 |
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from
Human Clinical Trials for New Cancer Drug |
| June 1 |
Annual Meeting of the Consortium of Multiple Sclerosis Centers
Focuses on the Challenges of Care and Research in Multiple
Sclerosis |
| June 1 |
EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in
Preclinical Models |
| June 1 |
Waismann Method Survey Reveals Dependency Risk for People Using
Suboxone |
| June 1 |
Pharmion to Present Clinical Data on Commercial and Pipeline
Products at 2007 American Society of Clinical Oncology (ASCO)
Meeting |
| June 1 |
World First Medical Treatment Announced by Researchers at Queen
Mary University London and University of Leicester |
| June 1 |
Sunesis Pharmaceuticals to Present Data at the 12th Congress of the
European Hematology Association |
| June 1 |
Top Line Results of Phase III Study in Acute Ischemic Stroke
(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and
Placebo |
| June 1 |
Topline Results of Phase III Study in Acute Ischemic Stroke
(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and
Placebo |
| June 1 |
ISTA Pharmaceuticals Announces Positive Preliminary Results from
Ecabet Sodium Phase IIb Study |
| June 1 |
Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal
Challenge of Live Virus, Pre-Clinical Data Show |
| June 1 |
CYT003-QbG10 to treat allergy to be presented at the Congress of
the European Academy of Allergology and Clinical Immunology
(EAACI), June 9-13, 2007 |
| June 1 |
CytImmune Presents Positive CYT-6019 Data During the American
Society of Clinical Oncology Annual Meeting in Chicago |
| June 1 |
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241
in Patients With Advanced Solid Tumors |
| June 1 |
Oncolytics Biotech Inc.'s Research Collaborators to Present
REOLYSIN Clinical Trial Data at ASCO Conference |
| June 1 |
Vakzine Projekt Management Reports Positive Clinical Trial Results
With Their Therapeutic Prostate Cancer Vaccine VPM4001 |
| June 1 |
Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data
at ASCO |
| June 1 |
Poniard Pharmaceuticals Announces Promising Data From Interim
Safety Analysis of Phase 1 Combination Trials of Picoplatin in
Colorectal and Prostate Cancers |
| June 1 |
Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer
Treatment |
| June 1 |
Pharmacyclics Announces Promising Results From Phase 2 Clinical
Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung
Cancer |
| June 1 |
OXiGENE Abstracts Published in ASCO Program |
| June 4 |
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting |
| June 4 |
SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in
Phase 2 Malignant Melanoma Trial |
| June 4 |
MabThera Significantly Extends Survival And Cures More Patients
With Aggressive Lymphoma Than Chemotherapy Alone |
| June 4 |
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in
Phase 2 Trial |
| June 4 |
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II
trial of Cloretazine (VNP40101M) in Patients with Relapsed or
Refractory Small Cell Lung Cancer |
| June 4 |
Promising Results with Epratuzumab and Chemotherapy in Children
with Acute Lymphoblastic Leukemia |
| June 4 |
GenVec Announces Update of Safety and Efficacy Data from Pivotal
Phase II/III PACT Study of TNFerade at ASCO |
| June 4 |
New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting |
| June 4 |
Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ASCO Annual Meeting |
| June 4 |
Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting |
| June 4 |
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data
on Molecular Imaging Pharmaceutical for Prostate Cancer |
| June 4 |
Nexavar Significantly Extends Overall Survival by 44% in Liver
Cancer Patients |
| June 4 |
Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin |
| June 4 |
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial
in B-Cell Chronic Lymphocytic Leukemia |
| June 4 |
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO |
| June 4 |
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Epothilone KOS-1584 at ASCO |
| June 4 |
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data
at Society Of Nuclear Medicine 2007 Annual Meeting |
| June 4 |
Phase 2 Clinical Results of Ganite Plus Standard Therapy in
Patients with Relapsed/Refractory Lymphoma Presented at ASCO |
| June 4 |
Cardiome And Astellas Announce Positive Results From ACT 2 Trial |
| June 4 |
Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer
Study |
| June 4 |
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO |
| June 4 |
Access and Somanta Announce Data to be Presented on Angiolix at
ASCO Oncology Conference |
| June 4 |
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO |
| June 4 |
Diatos Announces Positive Clinical Results for its DTS-201
Doxorubicin Prodrug Program |
| June 4 |
Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer
Patients Treated with Therapy Based on Ratiometric Dosing |
| June 4 |
Newly Published Data Demonstrates Superiority of Cipralex Over
Duloxetine for Acute Treatment of Depression |
| June 4 |
Updated Overall Survival Data From Pivotal Herceptin Adjuvant
Studies in HER2-Positive Breast Cancer |
| June 4 |
Evotec Reports Positive Proof-of-Concept Top-Line Results with
Insomnia Drug Candidate EVT 201 |
| June 4 |
New Data Show Pfizer's Axitinib Prolonged Overall Survival in
Advanced Pancreatic Cancer When Combined with Standard of Care
Chemotherapy |
| June 4 |
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and
Effective in Colorectal Cancer with Liver Metastases |
| June 4 |
Soliris Effective in PNH Patients With History of Aplastic Anemia
and Myelodysplastic Syndromes |
| June 4 |
Adding Thalidomide to Standard Therapy Improves Survival in Newly
Diagnosed Multiple Myeloma Patients Over Age 75 |
| June 4 |
Positive Results for Second-Generation Taxus Liberte Coronary Stent
System Highlighted in Journal of American College of Cardiology |
| June 4 |
The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved
Progression Free Survival When Given Before and After Surgery in
Patients With Resectable Liver Metastases From Colorectal Cancer |
| June 4 |
Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New
Treatment Benchmark in Patients With Metastatic Colorectal Cancer |
| June 4 |
Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival
Compared to Chemotherapy Alone for Sarcoma Cancer Patients |
| June 4 |
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting |
| June 4 |
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting |
| June 4 |
New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings |
| June 4 |
Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment |
| June 4 |
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of
GVAX Immunotherapy for Pancreatic Cancer |
| June 4 |
Dasatinib Shows High Early Response Rate as First Treatment for
Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report |
| June 4 |
ChemGenex Reports Successful Personalized Dosing of Quinamed at
ASCO |
| June 4 |
Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line
Results with ... |
| June 4 |
Phase 2 Clinical Results of Ganite Plus Standard Therapy in
Patients with Relapsed/Refractory Lymphoma Presented at ASCO |
| June 4 |
Hana Biosciences Presents Data On Two Programs At the American
Society of Clinical Oncology Annual Meeting |
| June 4 |
Cipralex demonstrates superiority to duloxetine for acute treatment
of depression in new study |
| June 4 |
Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an
Important Treatment Option for Patients With Metastatic Colorectal
Cancer |
| June 4 |
Merck at ASCO 2007: Encouraging Results in Progression-Free
Survival in Patients With Aggressive Brain Tumors (glioblastoma)
Using Cilengitide in Phase I/IIa Study |
| June 4 |
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM) |
| June 4 |
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved
Survival, Tumor Responses and Predictive p53 Biomarker |
| June 4 |
Pharmexa A/S (DK) - Long lasting immune response and survival to
RAS vaccine |
| June 4 |
Hemispherx Presents Evidence of Ampligen Synergies with Existing
Antivirals at International Avian Influenza Conference |
| June 4 |
News from the Battlefield of Metastatic Cancer: Epeius
Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G)
from the Stone of Chemistry and Physics |
| June 4 |
Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA
Nanoparticles |
| June 4 |
Study Shows Velcade Plus Doxil Improves Survival in Previously
Treated Patients With Multiple Myeloma |
| June 4 |
GSK'S Pazopanib Shows Positive Results in Patients with Advanced
Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma |
| June 4 |
8-Year Long-term Data Demonstrate Prolonged Overall Survival and
Length of Disease Remission with Bexxar |
| June 4 |
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard
of Care in Second Line Treatment of Small Cell Lung Cancer |
| June 4 |
Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in
Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) |
| June 4 |
New Data on Market-Leading Velcade (Bortezomib) for Injection
Further Strengthen Role in Previously Treated Multiple Myeloma |
| June 5 |
NovaDel Announces Positive Data from Two Studies Comparing Zolpidem
Oral Spray to Ambien Tablets |
| June 5 |
XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine
or Vinorelbine in Treating Non-Small Cell Lung Cancer |
| June 5 |
Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study
Presented at ASCO |
| June 5 |
Nuvelo Announces Publication of Preclinical Study Results
Demonstrating the Potential of NTB-A as a New Target for Leukemia
and Lymphomas |
| June 5 |
Repros' Androxal Shows Highly Statistically Significant Positive
Effects in Men with Secondary Hypogonadism |
| June 5 |
Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S.
Phase I REOLYSIN Trial |
| June 5 |
Study Shows Advantages of Complete Phase Ib Trial Over Separate
Phase I Trials |
| June 5 |
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly
Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer
Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by
Paclitaxel |
| June 5 |
New Data Shows Promising Antitumor Activity with nab-paclitaxel
(ABRAXANE) in Combination and as a Single Agent for the Treatment
of Lung and Ovarian Cancers |
| June 5 |
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American
Society of Clinical Oncology (ASCO) Annual Meeting |
| June 5 |
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III
Melanoma Demonstrated Significant and Sustained Impact on
Relapse-Free Survival |
| June 5 |
Caelyx Delays Time to Disease Progression as Maintenance Therapy in
Patients with Metastatic Breast Cancer |
| June 5 |
Updated Study Results Reinforce Survival Benefit of Taxotere
(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate
Cancer |
| June 5 |
OSI Pharmaceuticals Summarizes Data on Tarceva (erlotinib) at the
2007 American Society of Clinical Oncology (ASCO) Meeting |
| June 5 |
Stanford Researchers Track Human Stem Cells Transplanted Into Rat
Brain |
| June 5 |
Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine)
Data Published in Pain Medicine |
| June 5 |
MGI Pharma Summarizes Data Presented at the 2007 American Society
of Clinical Oncology (ASCO) Annual Meeting |
| June 5 |
ChemGenex Reports Successful Personalized Dosing of Quinamed at
ASCO |
| June 5 |
Clinical Data Reported on Vidaza in Hematologic Malignancies and
Advanced Solid Tumors |
| June 5 |
Synta Presents Results for STA-4783 in Metastatic Melanoma Showing
Improvement in Overall Survival |
| June 5 |
Synta Pharmaceuticals to Host Conference Call Today |
| June 5 |
Data Demonstrated Metastatic Melanoma Response to Investigational
Immunotherapy Ipilimumab |
| June 5 |
Encouraging Clinical Activity of GSK's Novel Cancer
Immunotherapeutic Confirmed in Phase II Study in Patients with Most
Common Form of Lung Cancer |
| June 5 |
IDM Pharma Presents Preliminary Results from Phase II UVIDEM
Melanoma Vaccine Clinical Trial |
| June 5 |
Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine)
Clinical Data at the Annual NCDEU Meeting |
| June 5 |
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
Age |
| June 5 |
Clinical Trial Results Change Standard of Care for Pancreatic
Cancer Patients, Future Therapies Discussed |
| June 5 |
Infinity and MedImmune Present Updated Phase I Results of IPI-504
in GIST at ASCO Annual Meeting |
| June 5 |
Gloucester Pharmaceuticals Reports Positive Interim Phase II Data
on Romidepsin for T-Cell Lymphomas at the 2007 American Society of
Clinical Oncology Annual Meeting |
| June 5 |
Cogane Data Presented at ‘11th International Congress of
Parkinson’s Disease and Disorders’ |
| June 5 |
Theratechnologies: TH9507 Phase 3 Clinical Update |
| June 5 |
Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of
Erbitux for Colorectal and Head and Neck Cancer Patients |
| June 5 |
Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal
Antibody IMC-A12 Presented at ASCO |
| June 5 |
Extensive Clinical Data on Erbitux Presented at the 2007 ASCO
Annual Meeting |
| June 5 |
Immunomedics Reports Initial Clinical Results With Hpam4 For
Pancreatic Cancer Therapy |
| June 5 |
Elixir Pharmaceuticals Presents Additional Preclinical Data
Demonstrating the Potential of Ghrelin Antagonism to Regulate
Metabolism, Body Weight and Glycemic Control |
| June 5 |
Interim Data From RECORD Study Show No Significant Difference
Between Avandia and Standard Therapy in Risk of Cardiovascular
Hospitalization or Death |
| June 6 |
Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer
Study Presented at ASCO |
| June 6 |
Savient Pharmaceuticals Announces Acceptance of Two Gout-Related
Abstracts for Poster Presentation at the European League Against
Rheumatism (EULAR) 2007 Annual Congress |
| June 6 |
Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with
Electroporation DNA Delivery Technology and New Devices at Gene
Therapy Meeting |
| June 6 |
XTL Provides Update on Phase I Clinical Trial of XTL-2125 |
| June 6 |
Statement by Philip Home Chairman of the RECORD Study Steering
Committee and Professor of Diabetes Medicine at Newcastle
University in England |
| June 6 |
MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the
American Headache Society Meeting |
| June 6 |
Medivation to Host Conference Call to Discuss Top-Line 12-Month
Results From Dimebon Alzheimer's Disease Study |
| June 6 |
Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well
Tolerated in Phase 3 Study |
| June 6 |
Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease
Presented at International Congress of Parkinson's Disease and
Movement Disorders |
| June 6 |
Santaris Pharma Presents Positive Clinical Data on SPC2996 in
Chronic Lymphocytic Leukaemia |
| June 6 |
Genta Announces Results of Phase 1 Study Using Genasense
Administered by Intermittent Subcutaneous Injection |
| June 6 |
Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory
Compound, Shows Efficacy in Psoriasis |
| June 6 |
Newly Published Data from Large Study Support Cardiovascular Safety
of Avandia (Rosiglitazone Maleate) |
| June 6 |
Metabasis Therapeutics Presents Results of Preclinical Studies for
MB07811, Its Novel Product Candidate for the Treatment of
Hyperlipidemia, at the Endocrine Society's Annual Meeting |
| June 6 |
New Data Confirms Significant Improvement of Disease Signs and
Symptoms in Patients with Rheumatoid Arthritis |
| June 7 |
OREXIGEN Therapeutics Announces Sustained-Release Formulation of
Zonisamide Shows Improved Tolerability When Compared to Immediate
Release Formulation |
| June 7 |
Novel Mechanism Insights and Additional Data on CombinatoRx Drug
Candidates to Be Presented at Upcoming EULAR Meeting |
| June 7 |
Dynogen Reports Positive Results in Phase 1B GERD Study |
| June 7 |
Phase III Study Evaluating Gilead's Viread for the Treatment of
Chronic Hepatitis B Virus Meets Primary Endpoint |
| June 7 |
Mymetics' HIV Vaccine Demonstrates First-Ever Production of
Neutralizing IgA Antibodies in Non-Human Primate Model |
| June 7 |
Landmark Study Published in the New England Journal of Medicine
Shows Important Benefits of Eprodisate (KIACTA) Treatment for
Patients with Amyloid A (AA) Amyloidosis |
| June 7 |
Archimedes Pharma Presents Positive Efficacy and Safety Data on
Nasalfent at European Association for Palliative Care Congress |
| June 7 |
Indevus Reports Positive Data From Phase III NEBIDO Trial |
| June 7 |
Human Genome Sciences Announces Positive Final Results Of Phase 2b
Trial of Albuferon |
| June 7 |
Merck's Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study |
| June 7 |
Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's
AAGP |
| June 7 |
Prana Biotechnology Presents New Key Findings on PBT2 |
| June 7 |
Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedical's Electroporation DNA Delivery Technology |
| June 7 |
To Stent or Not: Is That the Question? |
| June 7 |
NeurogesX Announces Presentation of Positive Phase 3 Clinical Data
at the Second International Congress on Neuropathic Pain Meeting
(NeuPSIG) |
| June 7 |
Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study |
| June 8 |
Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune
Deficiency |
| June 8 |
ApoCell's Cancer Predictive Index Helps Oncologists Select the Most
Effective Targeted Drug Therapy |
| June 8 |
Promising Data on Cognitive Effects of Safinamide in Early
Parkinson's Disease |
| June 8 |
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic
Peripheral Neuropathic Pain at International Congress on
Neuropathic Pain |
| June 8 |
International Movement Disorder Specialists Receive New Information
About the Use of Once-Daily Azilect in the Treatment of Parkinson's
Disease |
| June 8 |
Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the
Annual Meeting of the Associated Professional Sleep Societies |
| June 8 |
Further Statistical Analysis of the Recent Phase III trial on Lead
Product M6G Shows Additional Benefits |
| June 8 |
Archemix Announces Completion of Phase 1 Trial of ARC1779 |
| June 8 |
Eurand to Present Zentase Phase III Data |
| June 8 |
Trial Results with Intranasal Fentanyl Hold Promise for Treatment
of Breakthrough Pain in Cancer |
| June 8 |
NuPathe Reports Positive Phase One Results for NP101 Transdermal
Therapy for Acute Migraine |
| June 8 |
ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at
American Headache Society Meeting |
| June 8 |
Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free
Response Across Multiple Attacks |
| June 8 |
IMPAX Presents at Movement Disorder Society's 11th International
Congress of Parkinson's Disease and Movement Disorders |
| June 11 |
Research Indicates Geron's Human Embryonic Stem Cell-Based
Therapeutic for Spinal Cord Injury Evades Direct Attack by the
Human Immune System |
| June 11 |
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two
Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of
the European Hematology Association |
| June 11 |
Fractionated Radioimmunotherapy With (90)Y-epratuzumab in
Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II
Study |
| June 11 |
Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial
of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable
Cytogenetics at EHA Meeting |
| June 11 |
Frova Phase III Study Data Demonstrates That Short-Term Prevention
Treatment Reduces Frequency and Severity of Menstrual Migraine |
| June 11 |
Orchestra Therapeutics Announces New Phase II Clinical Data on
NeuroVax Demonstrating Marked Expansion of Regulatory T Cell
Populations in Patients With Multiple Sclerosis |
| June 11 |
Treating Heart Disease Risk Factors May Slow Alzheimer's Disease
Progression |
| June 11 |
Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive
Heart Failure Presented at Late-Breaking Session of Heart Failure
Congress 2007 |
| June 11 |
Pivotal Phase III Trial Showed Promacta (eltrombopag olamine)
Raised Platelet Counts and Reduced Bleeding in Patients With
Chronic ITP |
| June 11 |
Favrille Announces Data From Phase 2 Clinical Trial of FavId for
Indolent B-Cell Non-Hodgkin's Lymphoma in Europe |
| June 11 |
Phase III Clinical Trial with 4-Month Long-Acting Formulation of
Triptorelin: Ipsen Decides Not to Perform Further Administration |
| June 11 |
Medivation's Dimebon Maintains Statistically Significant Benefit on
All Five Efficacy Endpoints in Alzheimer's Disease Trial After One
Year of Therapy |
| June 11 |
Opexa Presents Tovaxin Research at Federation of Clinical
Immunology Societies Annual Meeting |
| June 11 |
Karo Bio Announces Sucessfule Phase II Results of KB2115 |
| June 11 |
Studies Show Efficacy and Safety of Alexion's Soliris in Broad
Population of PNH Patients |
| June 11 |
Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease |
| June 11 |
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial as Compared to Neostigmine |
| June 11 |
At the 2007 Alzheimer's Association International Conference on the
Prevention of Dementia - Neurochem's U.S. Principal Investigator
Presents Update on Tramiprosate (Alzhemed) |
| June 11 |
Data Showing that ReGen's Colostrinin Supports Healthy Cognitive
Function Presented at the 2007 International Congress on Natural
Medicine in Australia |
| June 11 |
Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA |
| June 11 |
Myriad Genetics Presents Mathematical Comparison of Disease
Modification Trial Designs at Alzheimer's ConferenceCurrent
Flurizan Phase 3 Study Design May Demonstrate Disease Modification |
| June 11 |
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial Compared to Neostigmine |
| June 11 |
Gabapentin Shown Effective for Fibromyalgia Pain |
| June 11 |
NCI Researchers Discover Genes That Are Turned on at High Levels in
Tumor-associated Blood Vessels of Mice and Humans |
| June 12 |
Inspire Announces Presentations at Two European Scientific
Conferences |
| June 12 |
Indevus Announces Presentation of Pagoclone Data at 47th Annual New
Clinical Drug Evaluation Unit Meeting |
| June 12 |
Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good
Pharmacokinetics and Tolerability in Phase I/II Trial |
| June 12 |
Accera, Inc. Announces Open-Label Data from Phase II Study in
Alzheimer's Disease at International Conference on Prevention of
Dementia |
| June 12 |
Valopicitabine Combined with Standard of Care Cleared Hepatitis C
Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a
Phase II Trial |
| June 12 |
Neurogen Proprietary Insomnia Compound Data Presented at Associated
Professional Sleep Societies Annual Meeting |
| June 12 |
Repros Reports That Proellex Has Demonstrated Superior Efficacy and
Safety in Endometriosis When Compared to Standard of Drug Care |
| June 12 |
Ivivi's PEMF Technology Significantly Improves Neuron Survival in
Parkinson's Disease Model, Study Finds |
| June 12 |
July Issue of Journal of Antimicrobial Chemotherapy Highlights
Study of Factive Tablets for Five-Day Treatment of
Community-Acquired Pneumonia |
| June 12 |
Critical Therapeutics Announces the Publication of Data for ZyfloCR
(Zileuton) Extended-Release Tablets in the Journal of Asthma |
| June 12 |
CuraGen Presents Update on Clinical Development Program for
Belinostat |
| June 12 |
Neurocrine Biosciences Announces New Research Studies Presented at
APSS Reveal Significant Under-Diagnosis of Insomnia |
| June 12 |
Women Well-Informed About Breast Cancer, Yet Lacking Knowledge
About Current Treatments, New Survey Finds |
| June 13 |
Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial |
| June 13 |
Enbrel Safety Data for up to Eight Years in Patients with Juvenile
Rheumatoid Arthritis Being Presented at EULAR |
| June 13 |
Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment |
| June 13 |
EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3
Clinical Trial at 47th Annual NCDEU Meeting |
| June 14 |
Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139
Presented at EULAR |
| June 14 |
Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's
Disease |
| June 14 |
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and
Maintenance vs. Placebo |
| June 14 |
Neurogen Proprietary Insomnia Compound Data for Two Studies
Presented at Associated Professional Sleep Societies Annual Meeting |
| June 14 |
Study Demonstrated Rozerem (ramelteon) Does Not Affect
Middle-of-the-Night Balance in Older Adults with Insomnia |
| June 14 |
Prolexys Pharmaceuticals and Columbia University Researchers
Publish Study on Anti-Tumor Properties of a Selective Small
Molecule Anti-Tumor Agent With Novel Mechanism of Action |
| June 14 |
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B
Showed Significant Reductions in Disease Activity in Patients with
Active Systemic Lupus Erythematosus |
| June 14 |
Targeted Genetics Reports Inflammatory Arthritis Clinical Data at
European Rheumatology Conference |
| June 14 |
Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid
Arthritis |
| June 14 |
Algeta Demonstrates Targeted Cancer-killing Potential of Novel
Alpha Particle Linked Antibodies in Leading Medical Journal Blood |
| June 14 |
Can-Fite Proceeds with Development of Third Drug; Progress in
Development of CF502 Will Be Presented at the Annual European
Congress of Rheumatology |
| June 14 |
Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid
Arthritis Study |
| June 14 |
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in
Lamellar Ichthyosis |
| June 14 |
Pharmasset Presents Clevudine and Racivir Data at the International
HIV Drug Resistance Workshop |
| June 14 |
Haemacure Announces Preliminary Findings of its Plasma Discard
Analysis |
| June 14 |
PARI Pharma Presents Study Results of Sinus Delivery and Inhaled
Liposomal Ciclosporin A at European Cystic Fibrosis Conference |
| June 14 |
Ambrilia Highlights Encouraging Data for its HIV Integrase
Inhibitor Program and Recent Developments at Annual Meeting |
| June 15 |
Investigational Study Demonstrated a Re-Establishment of Clinical
Improvement with Orencia (Abatacept) in Children with Juvenile
Idiopathic Arthritis upon Re-Introduction of Therapy |
| June 15 |
Solstice Neurosciences Presents Escalating Dose Study at
International Congress in Istanbul, Turkey |
| June 15 |
Remicade Two Year Data in Ankylosing Spondylitis Show Improvement
in Spinal Mobility and Spinal Inflammation |
| June 15 |
New Positive Pre-clinical Data for Active Biotech's RA Project I-3D |
| June 15 |
GlaxoSmithKline and Genmab Present Positive Phase II Results With
ofatumumab in Patients With Rheumatoid Arthritis (RA) |
| June 15 |
Lumiracoxib Study Showed Significantly Less Impact on Blood
Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled
Hypertension |
| June 15 |
Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07
Teleconference to Answer Questions About TA-65, Their Telomerase
Activator With Proven Age Management Benefits |
| June 15 |
Next Safety, Inc.'s Innovative Drug Delivery System Will Replace
Cigarettes and Significantly Advance Pulmonary Medication Delivery |
| June 15 |
Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid
Arthritis Compared to a Current Standard of Care |
| June 15 |
Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work
Productivity in Patients with Rheumatoid Arthritis |
| June 15 |
Prexige Study Shows Significantly Less Impact on Blood Pressure
Than Ibuprofen in Osteoarthritis Patients with Controlled
Hypertension |
| June 15 |
New Research Demonstrates Broad Efficacy of Azixa (MPC-6827)
Against Multiple Tumor Types and in Drug Resistant Cell Lines |
| June 15 |
Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal
Women with Early Breast Cancer Receiving Treatment with Tamoxifen |
| June 18 |
New Flu Vaccine From PepTcell Could Provide Immunity Against All
Strains of Influenza Virus |
| June 18 |
Salix Pharmaceuticals Announces Positive Top Line Results of
Balsalazide Tablets Registration Study |
| June 18 |
VeroScience Late-Breaking Abstract on Cycloset (A Quick Release
Formulation of Bromocriptine Mesylate) Accepted for Poster
Presentation at American Diabetes Association 67th Scientific
Sessions |
| June 18 |
Novelos Therapeutics Announces Encouraging Results in Ongoing Phase
2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care |
| June 18 |
Genzyme Announces Results of Clinical Trials Investigating Powder
Form of Sevelamer Carbonate |
| June 18 |
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure
Reduction During Important Early Morning Period When Most Adverse
Cardiovascular Events Occur |
| June 18 |
Genzyme Announces Results of Clinical Trials Investigating Powder
Form of Sevelamer Carbonate |
| June 18 |
Active Biotech presents new pre-clinical data for the 57-57 project
at the 8th World Congress on Inflammation |
| June 18 |
Advanced Viral Research Corp. Announces Positive Preliminary
Findings from Ongoing Phase II Dermatological Study |
| June 18 |
BioCryst Presents Phase I Peramivir Data at the Options for the
Control of Influenza Conference |
| June 18 |
First single breast cancer study to show significant survival
benefit for women switching from tamoxifen to Arimidex |
| June 19 |
Velcade (bortezomib) for Injection Survival Data in Front-Line
Multiple Myeloma Patients to be Featured at 11th International
Myeloma Workshop |
| June 19 |
Vical Licensee AnGes MG Announces Positive Results of Phase 3
Angiogenesis Trial in Japan |
| June 19 |
New Flu Vaccine from PepTcell Could Provide Immunity Against All
Strains of Influenza Virus |
| June 19 |
Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial
Data |
| June 19 |
Genaera to Present Preclinical Data on Trodusquemine for the
Treatment of Obesity at the American Diabetes Association 67th
Scientific Sessions |
| June 19 |
Research Documents Scalable Production, Survival Following
Engraftment and Positive Impact on Cardiac Function in Infarcted
Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for
Heart Failure |
| June 19 |
Allos Therapeutics Reports Results for Phase 3 Enrich Study of
Efaproxyn in Women With Brain Metastases Originating From Breast
Cancer |
| June 19 |
Clot-dissolving Agent May Be Beneficial in Treatment of Severe
Frostbite |
| June 19 |
Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in
Journal of American College of Cardiology |
| June 19 |
Trophos Publishes ALS Article in Journal of Pharmacology and
Experimental Therapeutics |
| June 19 |
Eurand's Zentase Effective in Treating Exocrine Pancreatic
Insufficiency, Studies Show |
| June 19 |
New Data Presented on Micardis (Telmisartan) Tablets in
Hypertensive Patients With Type 2 Diabetes |
| June 19 |
New Study Shows That telmisartan has Greater Renoprotective
Potential Thanlosartan in Hypertensive Patients With Type 2
Diabetes |
| June 20 |
Second Successful Quigley QR-443 Study Suggests Method of Action
Relevant to Broad Range of Chronic Inflammatory Diseases - Human
Study to Follow - |
| June 20 |
First Demonstration of nanoImmunology: a Nanomaterials-based
Therapeutic Approach to Treat Allergy |
| June 20 |
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,
Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for
Clinical Development in Chronic Hepatitis C Virus Infection |
| June 20 |
Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory
Drugs |
| June 20 |
Amylin Pharmaceuticals to Present New Data from Broad Diabetes and
Obesity Programs at ADA 2007 |
| June 20 |
Avalon Pharmaceuticals Announces Positive Interim Results For
AVN944 Phase I Trial |
| June 20 |
Modigene Announces Successful Completion of Pharmacokinetic &
Pharmacodynamic Pre-Clinical Experiments for Proprietary
Long-Acting Human Growth Hormone, Long-acting Interferon Beta and
Long-acting Erythropoietin |
| June 20 |
Millipore Corporation Announces New ReNcell Data from Collaboration
with ReNeuron |
| June 20 |
ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin
Conjugate Data Presented at American Diabetes Association Annual
Meeting |
| June 20 |
Fact Sheet: Advancing Stem Cell Research While Respecting Moral
Boundaries |
| June 20 |
President Bush Ignores America's Plea for Support of Stem Cell
Research |
| June 20 |
Infertile Voice Supports Stem Cell Research: RESOLVE Calls for
Patient Options in Using Frozen Embryos |
| June 20 |
Materia Licenses Metathesis Catalyst Platform to Eisai |
| June 20 |
Researchers Discover Gene For Rare Skin Disorder |
| June 20 |
Vastox Awarded £400,000 Grant to Support R&D at
Carbohydrate Chemistry Facility |
| June 20 |
Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint |
| June 20 |
SemBioSys to present new data at American Diabetes Association
annual meeting |
| June 20 |
The Christopher and Dana Reeve Foundation Expresses Disappointment
Over President Bush's Veto of the Stem Cell Research Enhancement
Act |
| June 20 |
Biodel Inc. to Present VIAject Clinical Progress at the 2007
American Diabetes Association Meeting |
| June 20 |
Dean: President Bush Has Turned His Back on the American People |
| June 21 |
Apollo's human proteins boost stem cell research |
| June 21 |
New Report 'Looking at Chiral Technologies' Analyzes the Global
Market Growth Forecasts Driven By Two Very Important Components as
Single Isomer Drugs and Single Enantiomer Pharmaceuticals |
| June 21 |
Pharmexa A/S (DK) - Pharmexa presents data from influenza program |
| June 21 |
Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 23 |
| June 21 |
New Analysis of WHI Data Shows Reduced Levels of Coronary Artery
Calcification, a Predictor of Cardiovascular Events, in Women aged
50-59 taking Estrogen Therapy |
| June 21 |
Diabetes drug supported by Mexican Diabetes Federation |
| June 21 |
Arterial Plaque Significantly Reduced in Women Age 50-59 Taking
Hormones, Says New Analysis of Women's Health Initiative Data |
| June 21 |
Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia
Clinical Trial |
| June 21 |
Research on New Treatment for Neglected Disease Published in The
New England Journal of Medicine |
| June 21 |
Liraglutide provides significantly better glucose control than
insulin glargine in phase 3 study |
| June 21 |
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Extension Trial with Tovaxin for Multiple Sclerosis |
| June 21 |
Obama Statement on Bush Veto of Stem Cell Bill |
| June 21 |
Advanced Cell Technology Develops First Human Embryonic Stem Cell
Line without Destroying an Embryo |
| June 21 |
Remarks by President Bush on Stem Cell Veto and Executive Order |
| June 21 |
Answerthink and LORENZ Life Sciences Group Announce Strategic
Alliance for the SAP Life Science Industry |
| June 21 |
Pelosi: Bush Veto of Stem Cell Bill Says 'No' to the Hopes of
Million of Families Across America |
| June 21 |
Pieris Progresses Development of its Proprietary Biotherapeutics
Platform: Successful Demonstration of Dual Targeting With
Duocalin(R) Technology |
| June 21 |
Nationwide MRSA Prevalence Study to Demonstrate Full Scope of
'Superbug' Threat Facing U.S. Healthcare Facilities and Patients |
| June 21 |
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
Urology Meetings |
| June 21 |
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy
with AP 12009 in Recurrent Anaplastic Astrocytoma |
| June 21 |
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.
Urology Meetings |
| June 21 |
Malvern initiates European user group meetings for chemical imaging |
| June 21 |
AMIA Announces 2008 Summit on Translational Bioinformatics |
| June 21 |
PromegaExpress Expands Easy Access to Products with New Cabinet |
| June 21 |
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating
MacroVascular Outcomes Presented at the American Diabetes
Association 67th Scientific Sessions |
| June 21 |
Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,
AN2690; Findings Published in Science |
| June 22 |
MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2
Clinical Data at the World Asthma Meeting |
| June 22 |
deCODE Biostructures, Inc. Initiates New Research Collaboration
with Genus Onocology, LLC |
| June 22 |
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Mechanism of Action and Clinical Activity of
Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American
Diabetes Association 67th Scientific Sessions in Chicago, Illinois |
| June 22 |
Neurologix Announces Publication of Landmark Gene Therapy Study
Demonstrating Safety and Statistically Significant Improvement in
Patients With Advanced Parkinson's Disease |
| June 22 |
MaxCyte and Medinet to Present at the 13th Annual Meeting of the
International Society for Cellular Therapy (ISCT) in Sydney,
Australia |
| June 22 |
GenoLogics Announces Bioinformatics Partnership with Illumina |
| June 25 |
Neurogen Announces Positive Results for Proprietary Insomnia Drug
in Two Chronic Insomnia Clinical Trials |
| June 25 |
Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal |
| June 25 |
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its
Ghrelin Antagonist Program at the American Diabetes Association's
Annual Meeting |
| June 25 |
Elixir Pharmaceuticals Announces Clinical Data at American Diabetes
Association Conference Highlighting Ability of Glufast to Maintain
Glycemic Control in Patients with Type 2 Diabetes |
| June 25 |
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of
Improved Glycemic Control and Significant Reductions of
LDL-Cholesterol and C-Reactive Protein |
| June 25 |
Bentley Reports Positive Results with Nasulin Intranasal Insulin
Spray at the American Diabetes Association Meeting |
| June 25 |
VIVUS Announces Abstract Published at American Diabetes Association
Scientific Sessions |
| June 25 |
BioLife Solutions Presents Data on CryoStor at International
Society for Cellular Therapy Annual Meeting |
| June 25 |
New Data from Multiple Studies Show Galvus Delivers Consistent and
Robust Blood Sugar Control in Patients with Type 2 Diabetes |
| June 25 |
Positive Clinical Results for DG041 Lead Product Development
Highlights at deCODE R&D Event |
| June 25 |
Affymax Reports Phase 2 Clinical Dose Ranging Results of
Once-Per-Month Hematide for the Treatment of Anemia |
| June 25 |
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes
Using Self-Adjusted Dosing Starting With Once-Daily Insulin
Treatment Levemir |
| June 25 |
Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4
Inhibitor, ARI-2243, at the ADA |
| June 25 |
Phase IIIb Clinical Data Validate the Overall and Cardiovascular
Safety Profile of Cycloset (A Quick Release Formulation of
Bromocriptine Mesylate) in Patients with Type 2 Diabetes |
| June 25 |
Sangamo BioSciences Announces Presentation of Phase 1 ZFP
Therapeutic Data at American Diabetes Association Meeting |
| June 25 |
CytRx Announces Clinical Results from Its Rising Multiple Dose
Trial with Arimoclomol for ALS |
| June 25 |
Byetta Treatment for Three and a Half Years Associated with
Reductions in Cardiovascular Risk Factors in People with Type 2
Diabetes |
| June 25 |
Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for
the Treatment of Obesity at the American Diabetes Association 67th
Scientific Session |
| June 25 |
Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes |
| June 25 |
Second Phase III Study Evaluating Gilead's Viread for the Treatment
of Chronic Hepatitis B Virus Meets Primary Endpoint |
| June 25 |
Neuroblastoma Expert Reviews Progress and Challenges in Fighting
Difficult Pediatric Cancer |
| June 25 |
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog
Liraglutide, Brings Patients to A1c Target |
| June 25 |
New Poll Shows Men, Women Incorrectly Blame Symptoms of Low
Testosterone on Normal Aging |
| June 25 |
Second Phase III Study Evaluating Gilead's Viread for the Treatment
of Chronic Hepatitis B Virus Meets Primary Endpoint |
| June 25 |
Phosphagenics Announces Positive Proof of Concept Results from
Studies Utilizing Company's Dermal Drug Delivery Technology |
| June 25 |
HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove
Superior at International Conference |
| June 25 |
Largest National U.S. Healthcare Facility MRSA Study Reveals
Infection Rates Eight Times Greater Than Previous Estimates |
| June 25 |
Lipitor Reduced the Risk of Coronary Events by Half and Stroke by
Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who
Experienced a Recent Stroke |
| June 25 |
First Phase II Short-Term Study on Dapagliflozin Shows Results on
Safety, Tolerability and Glycemic Markers in Subjects With Type 2
Diabetes |
| June 25 |
Novagali Pharma Presents at AACO the Results of its Pivotal Phase
III Clinical Trial of Vekacia in Children Suffering From Vernal
Keratoconjunctivitis |
| June 25 |
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes
Using Self-Adjusted Dosing Starting With Once-Daily Insulin
Treatment Levemir |
| June 25 |
MediQuest Concludes Confirmatory Phase III Study of Raynaud’s
Therapy |
| June 26 |
Publication on Pixantrone Preclinical Studies Demonstrates Reduced
Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and
Mitoxantrone |
| June 26 |
SemBioSys Presents Positive Insulin Data at the American Diabetes
Association Conference |
| June 26 |
Tranzyme Pharma Presents Initial Phase IIa Data for its Novel
Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis |
| June 26 |
Replidyne Announces Positive Phase I Results for Topical Antibiotic
REP8839 |
| June 26 |
Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic
Control in Subjects with Type 2 Diabetes Compared to Metformin
Alone |
| June 26 |
ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical
Model |
| June 26 |
An Investigational Study Released at ADA Showed that Initial
Combination Therapy with Januvia (sitagliptin) and Metformin Led to
Improvement in Markers of Beta Cell Function in Patients with Type
2 Diabetes |
| June 26 |
Resveratrol Studies Suggest Broad Implications for SIRT1 Activation
in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease |
| June 26 |
Publication Confirms that EpCAM, the Target for Two of Micromet's
Product Candidates, Is Overexpressed on Cancer Stem Cells of
Certain Cancers |
| June 26 |
Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of
Blindness in Premature Infants |
| June 26 |
Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic
Control in Subjects with Type 2 Diabetes Compared to Metformin
Alone |
| June 26 |
Genetics Journal Thimerosal/Autism Study the 'Best Science Drug
Company Money Can Buy' |
| June 26 |
Expert Opinion Highlights Avigen's AV411 as Potential New
Therapeutic for Neuropathic Pain and Opioid Withdrawal |
| June 27 |
New Proof of Genistein's Efficacy and Safety for Osteopenia and
Osteoporosis Published in Annals of Internal Medicine |
| June 27 |
Columbia Laboratories Reports Positive Results from Multi-dose
Pharmacokinetic Study of Vaginally-administered Lidocaine |
| June 27 |
Two Phase III clinical trials on corifollitropin alfa (Org 36286)
reach randomization target |
| June 27 |
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer |
| June 27 |
CytRx Reports Promising Data from Its Open-Label Extension Clinical
Trial of Arimoclomol in ALS |
| June 27 |
In Vitro and In Vivo Data Show Alfacell's Onocanse is Active
Against Naive and Chemoresistant Neuroblastoma Cells |
| June 27 |
Aspreva and Roche Announce Preliminary Results for Phase III Study
Evaluating CellCept in Lupus Nephritis |
| June 27 |
Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's
Published Study on Culture Blood-Forming Stem Cells from Human Fat
Tissue as Supporting Near Term Benefits of Banking Adipose (Fat)
Derived Stem Cells |
| June 27 |
Opexa Advances Monocyte Derived Islet Technology to Proof of
Principle in stz-induced NOD/SCID Mice |
| June 27 |
Generex Biotechnology to Make Presentations At 46th Annual Meeting
of the European Society of Pediatric Endocrinology |
| June 27 |
Gentium's Defibrotide Seen as Active in Multiple Myeloma |
| June 27 |
Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for
Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical
Study |
| June 27 |
Lupus Foundation of America Statement on Results for Clinical Study
of CellCept Released by Aspreva Pharmaceutical Company |
| June 28 |
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients |
| June 28 |
Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis |
| June 28 |
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference |
| June 28 |
New Study Shows Hib Vaccine Protects Children From Significant
Burden of Life-Threatening Pneumonia and Meningitis |
| June 28 |
ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop |
| June 28 |
CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and
Pain, but Not CRP |
| June 28 |
Progenics and Wyeth Announce Positive Results from Three-Month
Clinical-Extension Study of Subcutaneous Methylnaltrexone for the
Treatment of Opioid-Induced Constipation in Patients with Advanced
Illness |
| June 28 |
Cytochroma Reports Positive Phase I Clinical Data for CTA018
Injection |
| June 28 |
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension |
| June 28 |
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types |
| June 28 |
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma |
| June 28 |
Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Quadramet at International Myeloma Workshop |
| June 28 |
Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
Myeloma Patients |
| June 28 |
Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma |
| June 29 |
Common Preterm Labor Drug Has More Side Effects Than Alternative,
Finds Study from Packard Children's Hospital and Stanford |
| June 29 |
The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece |
| June 29 |
New Study in Journal of Pediatrics Suggests Synagis (Palivizumab)
May Reduce Subsequent Recurrent Wheezing in Preterm Infants |
| June 29 |
The International Myeloma Foundation Says Data Reported at a Global
Medical Meeting in Greece Demonstrates Improved Survival for a Wide
Range of Myeloma Patients |
| June 29 |
Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies |
| June 29 |
Biotec Pharmacon Announces Preliminary Results from the
Sloan-Kettering Clinical Study |
| June 29 |
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase
II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple
Myeloma and Waldenstrom's Macroglobulinemia |
| June 29 |
European Society for Medical Oncology (ESMO) Presents Data from the
Clinical Trial of MediGene's Cancer-Killing Virus in Press
Conference |
| June 29 |
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib |
| June 29 |
Vaccine Can Prevent Cervical Cancer and Precancerous Lesions |
| June 29 |
RTA 402 Shown to Protect Animals Against Toxicities of Standard
Cancer Treatments |
| June 29 |
Advanced Life Sciences to Host Conference Call to Discuss Data From
Cethromycin's First of Two Phase 3 Pneumonia Trials |
| June 29 |
Labopharm to Present Poster on Dose Titration of Once-daily
Tramadol at 3rd International Forum on Pain Medicine |
